Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSN821 relative bioavailability and food-effect crossover study in healthy male volunteers
NL-OMON34811Phase 1Active, not recruiting
- Sponsor
- OSI Pharmaceuticals
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PSN821 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by OSI Pharmaceuticals. Primary endpoints: Pharmacokinetics of PSN821, Pharmacokinetics of PSN715297 and 1 more. Started Jan 2010; status: active, not recruiting.
02
Drugs
PSN821
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON34811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34811.